Phagos, a French biotechnology company pioneering AI-powered phage therapy, has raised €25 million (US$29 million) in a Series A funding round to accelerate its antibiotic-free solutions for livestock and expand globally. This marks a major milestone in the company’s mission to combat antimicrobial resistance (AMR) — a growing global threat to both human and animal health.
A Breakthrough in Veterinary Biotechnology
The company’s proprietary Alphagos™ platform integrates microbiology and artificial intelligence to identify bacterial pathogens, match them with effective phages, and create targeted, precision therapies that preserve the natural microbiome.
This precision approach could significantly reduce the overuse of antibiotics in animal farming — a critical step toward sustainable livestock management.
Funding Details & Strategic Goals
The €25 million Series A round was co-led by CapAgro, Hoxton Ventures, CapHorn, and Demeter, with participation from Acurio Ventures, Citizen Capital, Entrepreneur First, Founders Capital, and Station F.
Phagos plans to use the investment to:
- Deploy veterinary phage therapies in real-world farm settings.
- Enhance its AI-driven Alphagos™ discovery platform.
- Support international expansion across Europe, Asia, and the Americas.
- Grow its scientific and technical team to strengthen R&D and production capacities.
Addressing the Global AMR Crisis
The overuse of antibiotics in livestock has contributed to alarming levels of antimicrobial resistance. Phagos aims to replace these traditional antibiotics with eco-friendly phage therapies that are both species-specific and microbiome-safe, offering a sustainable path forward for global agriculture and food security.
Shaping the Future of Animal Health
Founded in 2021 by Alexandros Pantalis and Dr Adèle James, Phagos is the first company authorised to market personalized veterinary phage treatments within the European Union, a regulatory breakthrough that paves the way for large-scale field deployment.
With its cutting-edge platform and expanding partnerships, Phagos is positioning itself as a global leader in biotech innovation, bridging AI, microbiology, and sustainable agriculture to redefine how bacterial infections are managed in livestock.
The company’s long-term ambition is to extend its platform to human health, paving the way for precision phage therapies beyond veterinary medicine.
For more phage-related global news, check here
